Antihemophilic Factor Fc Fusion Protein Recombinant

Antihemophilic Factor Fc Fusion Protein Recombinant Brand Name– ELOCTATE

What is Antihemophilic Factor Fc Fusion Protein Recombinant

Antihemophilic Factor Fc Fusion Protein Recombinant is approved for adults and children with hemophilia A for control and prevention of bleeding episodes, management of bleeding during surgical procedures, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

The antihemophilic factor is linked to the Fc protein fragment of human IgG1, which prolongs factor circulation in the body and extends time between prophylactic infusions.

This product is not derived from human blood and contains no preservatives or added animal or human components. Recombinant antihemophilic factor, Fc fusion protein was FDA-approved in June 2014.

Indications

  • bleeding prophylaxis
  • hemophilia A
  • surgical bleeding

For the management of hemophilia A (congenital Factor VIII deficiency)

Side Effects

  1. abdominal pain
  2. anaphylactoid reactions
  3. angioedema
  4. antibody formation
  5. arthralgia
  6. bradycardia
  7. chest pain (unspecified)
  8. cough
  9. dizziness
  10. dysgeusia
  11. dyspnea
  12. headache
  13. hypertension
  14. hypotension
  15. injection site reaction
  16. malaise
  17. myalgia
  18. pruritus
  19. rash
  20. urticaria
  21. wheezing

Monitoring Parameters

  • clotting inhibitor titers
  • factor VIII concentrations

Contraindications

  • breast-feeding
  • factor VIII inhibitors
  • pregnancy

Interactions

  • Emicizumab
  • Factor VIIa, Recombinant
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top